Back to Search
Start Over
The reactive vaccination campaign against cholera emergency in camps for internally displaced persons, Borno, Nigeria, 2017: a two-stage cluster survey
- Source :
- BMJ Global Health, Vol 5, Iss 6 (2020), BMJ Global Health
- Publication Year :
- 2020
- Publisher :
- BMJ, 2020.
-
Abstract
- IntroductionIn 2017, amidst insecurity and displacements posed by Boko Haram armed insurgency, cholera outbreak started in the Muna Garage camp for Internally Displaced Persons (IDPs) in Borno State, Nigeria. In response, the Borno Ministry of Health and partners determined to provide oral cholera vaccine (OCV) to about 1 million people in IDP camps and surrounding communities in six Local Government Areas (LGAs) including Maiduguri, Jere, Konduga, Mafa, Dikwa, and Monguno. As part of Monitoring and Evaluation, we described the coverage achieved, adverse events following immunisation (AEFI), non-vaccination reasons, vaccination decisions as well as campaign information sources.MethodsWe conducted two-stage probability cluster surveys with clusters selected without replacement according to probability-proportionate-to-population-size in the six LGAs targeted by the campaign. Individuals aged ≥1 years were the eligible study population. Data sources were household interviews with vaccine card verification and memory recall, if no card, as well as multiple choice questions with an open-ended option.ResultsOverall, 12 931 respondents participated in the survey. Overall, 90% (95% CI: 88 to 92) of the target population received at least one dose of OCV, range 87% (95% CI: 75 to 94) in Maiduguri to 94% (95% CI: 88 to 97) in Monguno. The weighted two-dose coverage was 73% (95% CI: 68 to 77) with a low of 68% (95% CI: 46 to 86) in Maiduguri to a high of 87% (95% CI: 74 to 95) in Dikwa. The coverage was lower during first round (76%, 95% CI: 71 to 80) than second round (87%, 95% CI: 84 to 89) and ranged from 72% (95% CI: 42 to 89) and 82% (95% CI: 82 to 91) in Maiduguri to 87% (95% CI: 75 to 95) and 94% (95% CI: 88 to 97) in Dikwa for the respective first and second rounds. Also, coverage was higher among females of age 5 to 14 and ≥15 years than males of same age groups. There were mild AEFI with the most common symptoms being fever, headache and diarrhoea occurring up to 48 hours after ingesting the vaccine. The most common actions taken after AEFI symptoms included ‘did nothing’ and ‘self-medicated at home’. The top reason for taking vaccine was to protect from cholera while top reason for non-vaccination was travel/work. The main source of campaign information was a neighbour. An overwhelming majority (96%, 95% CI: 95% to 98%) felt the campaign team treated them with respect. While 43% (95% CI: 36% to 50%) asked no questions, 37% (95% CI: 31% to 44%) felt the team addressed all their concerns.ConclusionThe campaign achieved high coverage using door-to-door and fixed sites strategies amidst insecurity posed by Boko Haram. Additional studies are needed to improve how to reduce non-vaccination, especially for the first round. While OCV provides protection for a few years, additional actions will be needed to make investments in water, sanitation and hygiene infrastructure.
- Subjects :
- Male
medicine.medical_specialty
Adolescent
Cross-sectional study
media_common.quotation_subject
030231 tropical medicine
Population
cholera
Nigeria
cross-sectional survey
lcsh:Infectious and parasitic diseases
03 medical and health sciences
0302 clinical medicine
Hygiene
Surveys and Questionnaires
Humans
Medicine
lcsh:RC109-216
030212 general & internal medicine
Child
education
Original Research
media_common
Refugees
lcsh:R5-920
education.field_of_study
Immunization Programs
business.industry
Health Policy
Public health
public health
Public Health, Environmental and Occupational Health
vaccines
medicine.disease
Cholera
Vaccination
Child, Preschool
Internally displaced person
Female
lcsh:Medicine (General)
business
Cholera vaccine
Demography
Subjects
Details
- ISSN :
- 20597908
- Volume :
- 5
- Database :
- OpenAIRE
- Journal :
- BMJ Global Health
- Accession number :
- edsair.doi.dedup.....0cb630142d2b8e2a589c69388f1ffc51
- Full Text :
- https://doi.org/10.1136/bmjgh-2020-002431